Rexahn Pharmaceuticals, Inc.:製品開発パイプライン動向2015

【英語タイトル】Rexahn Pharmaceuticals, Inc. - Product Pipeline Review - 2015

Global Markets Directが出版した調査資料(GMDHC06965CDB)・商品コード:GMDHC06965CDB
・発行会社(調査会社):Global Markets Direct
・発行日:2015年4月22日
・ページ数:40
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD1,500 ⇒換算¥169,500見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD3,000 ⇒換算¥339,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD4,500 ⇒換算¥508,500見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Rexahn Pharmaceuticals, Inc. – Product Pipeline Review – 2015

Summary

Global Markets Direct’s, ‘Rexahn Pharmaceuticals, Inc. – Product Pipeline Review – 2015’, provides an overview of the Rexahn Pharmaceuticals, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Rexahn Pharmaceuticals, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Rexahn Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Rexahn Pharmaceuticals, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Rexahn Pharmaceuticals, Inc.’s pipeline products

Reasons to buy

- Evaluate Rexahn Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Rexahn Pharmaceuticals, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Rexahn Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Rexahn Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Rexahn Pharmaceuticals, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Rexahn Pharmaceuticals, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Rexahn Pharmaceuticals, Inc. Snapshot 5
Rexahn Pharmaceuticals, Inc. Overview 5
Key Information 5
Key Facts 5
Rexahn Pharmaceuticals, Inc. – Research and Development Overview 6
Key Therapeutic Areas 6
Rexahn Pharmaceuticals, Inc. – Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products – Monotherapy 10
Rexahn Pharmaceuticals, Inc. – Pipeline Products Glance 11
Rexahn Pharmaceuticals, Inc. – Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
Phase I Products/Combination Treatment Modalities 12
Rexahn Pharmaceuticals, Inc. – Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Discovery Products/Combination Treatment Modalities 14
Rexahn Pharmaceuticals, Inc. – Unknown Stage Pipeline Products 15
Unknown Products/Combination Treatment Modalities 15
Rexahn Pharmaceuticals, Inc. – Drug Profiles 16
RX-0201 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
RX-3117 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
RX-5902 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
RX-0047N 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
RX-0201N 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
RX-1792 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
RX-21101 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
RX-8243 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Small Molecules for Cancer 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Rexahn Pharmaceuticals, Inc. – Pipeline Analysis 26
Rexahn Pharmaceuticals, Inc. – Pipeline Products by Target 26
Rexahn Pharmaceuticals, Inc. – Pipeline Products by Route of Administration 27
Rexahn Pharmaceuticals, Inc. – Pipeline Products by Molecule Type 28
Rexahn Pharmaceuticals, Inc. – Pipeline Products by Mechanism of Action 29
Rexahn Pharmaceuticals, Inc. – Recent Pipeline Updates 30
Rexahn Pharmaceuticals, Inc. – Dormant Projects 37
Rexahn Pharmaceuticals, Inc. – Locations And Subsidiaries 38
Head Office 38
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 39
Disclaimer 40

[List of Tables]
Rexahn Pharmaceuticals, Inc., Key Information 5
Rexahn Pharmaceuticals, Inc., Key Facts 5
Rexahn Pharmaceuticals, Inc. - Pipeline by Indication, 2015 8
Rexahn Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015 9
Rexahn Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015 10
Rexahn Pharmaceuticals, Inc. - Phase II, 2015 11
Rexahn Pharmaceuticals, Inc. - Phase I, 2015 12
Rexahn Pharmaceuticals, Inc. - Preclinical, 2015 13
Rexahn Pharmaceuticals, Inc. - Discovery, 2015 14
Rexahn Pharmaceuticals, Inc. - Unknown, 2015 15
Rexahn Pharmaceuticals, Inc. - Pipeline by Target, 2015 26
Rexahn Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2015 27
Rexahn Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015 28
Rexahn Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015 29
Rexahn Pharmaceuticals, Inc. - Recent Pipeline Updates, 2015 30
Rexahn Pharmaceuticals, Inc. - Dormant Developmental Projects,2015 37

[List of Figures]
Rexahn Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2015 7
Rexahn Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015 9
Rexahn Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015 10
Rexahn Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2015 26
Rexahn Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2015 27
Rexahn Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2015 28
Rexahn Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015 29

【レポートのキーワード】

Rexahn Pharmaceuticals, Inc.、製品開発、製薬、医薬品、治験、研究開発、パイプライン

★調査レポート[Rexahn Pharmaceuticals, Inc.:製品開発パイプライン動向2015] (コード:GMDHC06965CDB)販売に関する免責事項を必ずご確認ください。
★調査レポート[Rexahn Pharmaceuticals, Inc.:製品開発パイプライン動向2015]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆